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Abstract
Smith-Magenis syndrome (SMS) is a complex neurobehavioral disorder characterized by multiple congenital anomalies. The
syndrome is primarily ascribed to a ,3.7 Mb de novo deletion on chromosome 17p11.2. Haploinsufficiency of multiple
genes likely underlies the complex clinical phenotype. RAI1 (Retinoic Acid Induced 1) is recognized as a major gene involved
in the SMS phenotype. Extensive genetic and clinical analyses of 36 patients with SMS-like features, but without the 17p11.2
microdeletion, yielded 10 patients with RAI1 variants, including 4 with de novo deleterious mutations, and 6 with novel
missense variants, 5 of which were familial. Haplotype analysis showed two major RAI1 haplotypes in our primarily
Caucasian cohort; the novel RAI1 variants did not occur in a preferred haplotype. RNA analysis revealed that RAI1 mRNA
expression was significantly decreased in cells of patients with the common 17p11.2 deletion, as well as in those with de
novo RAI1 variants. Expression levels varied in patients with familial RAI1 variants and in non-17p11.2 deleted patients
without identified RAI1 defects. No correlation between SNP haplotype and RAI1 expression was found. Two clinical
features, ocular abnormalities and polyembolokoilomania (object insertion), were significantly correlated with decreased
RAI1 expression. While not significantly correlated, the presence of hearing loss, seizures, hoarse voice, childhood onset of
obesity and specific behavioral aspects and the absence of immunologic abnormalities and cardiovascular or renal
structural anomalies, appeared to be specific for the de novo RAI1 subgroup. Recognition of the combination of these
features will assist in referral for RAI1 analysis of patients with SMS-like features without detectable microdeletion of
17p11.2. Moreover, RAI1 expression emerged as a genetic target for development of therapeutic interventions for SMS.
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Introduction
Smith-Magenis syndrome (SMS; OMIM 182290) is a complex
neurobehavioral syndrome characterized by multiple congenital
anomalies and behavior problems, including craniofacial and
skeletal abnormalities, variable intellectual disability, self-injurious
and attention-seeking behaviors, speech and motor delay, and
sleep disturbance [1,2,3,4,5]. The estimated prevalence of SMS in
the general population is ,1:15000–25000, but it is likely
underdiagnosed [6]. The syndrome is caused primarily by de novo
interstitial deletions of chromosome 17p11.2, which can range
from 1.5 to 9 megabases (Mb) in size, detectable by cytogenetic G-
banding and/or by fluorescence in situ hybridization (FISH)
analysis. The most common ,3.7 Mb deletion occurs in
approximately 75% of the patients [3,4,5,7,8].
Several genes have been mapped to the 17p11.2 SMS critical
region, and the exact functions of many of these genes remain
unknown [5,9,10]. Haploinsufficiency for several genes is likely to
account for the SMS phenotype, but haploinsufficiency for the
retinoic acid induced 1 gene (RAI1), located within the minimal
critical SMS deletion region, is considered to play a major role in
SMS. This is supported by the identification of heterozygous point
mutations in RAI1 in SMS patients without detectable 17p11.2
deletions. Such individuals share most, but not all, characteristics
of the SMS phenotype [11,12,13,14], but their levels of RAI1
mRNA transcription and RAI1 protein translation have not been
assessed.
The RAI1 gene (OMIM 607642; GenBank NM_030665)
consists of 6 exons, of which exons 3 through 6 encode a 1,906
amino acid RAI1 protein [15]. An RAI1 mRNA transcript of
approximately 8 kb is expressed in all adult and fetal tissues
examined [16], with heart and neuronal tissues showing the
highest expression levels [15]. RAI1 is thought to function as a
transcription factor, based on the presence of a bipartite nuclear
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(PHD) that is conserved in the trithorax group of chromatin-based
transcription regulators [12,17]. It also has homology to the
transcription factor TCF20 [16], and contains polyglutamine
(polyQ) stretches capable of modulating transcriptional activation
[18]. Recently, RAI1 was shown to localize to the nucleus and
have transcription factor activity in a neuronal cell line [19]. The
RAI1 promotor region contains several regulatory protein binding
sites, including a retinoic acid-responsive element [15]. A variety
of mouse studies have identified additional Rai1 features, including
upregulation of Rai1 in mouse carcinoma cells following retinoic
acid treatment [20], localization of the Rai1 mRNA transcript and
protein to neurons suggesting a role in neuronal differentiation
[20], and a dosage-dependent role for Rai1 in the serotonin
pathway [21].
To date, only 14 de novo RAI1 mutations (in 16 patients) have
been associated with SMS [9,10,11,12,13,14,22], so more patients
need to be evaluated to understand the complete role of RAI1 in the
SMS phenotype. We analyzed 36 patients with SMS features but
without a detectable 17p11.2 microdeletion, for variations in RAI1
and RAI1 SNP haplotypes. We report 4 de novo RAI1 mutations, 1
unclassified variant, and 5 novel familial variants. In addition, we
demonstrate for the first time that RAI1 mRNA expression is
decreased inlymphoblastoidcells ofSMSpatients with thecommon
17p11.2 deletion, as well as in cells with RAI1 mutations. We also
extensively compare the clinical features of patients bearing the
common 17p11.2 deletion with the manifestations of patients
having RAI1 variants, to further delineate which aspects of the SMS
phenotype are influenced by RAI1 expression.
Results
Copy Number Analysis
Of ,120 investigated patients with SMS features, 36 were
cytogenetically ascertained to have no detectable deletion of
17p11.2. For patients without prior cytogenetic studies, FISH
analysis was performed (Figure 1A). Genomic DNA from whole
blood was then used to confirm the presence of two RAI1 alleles in
all 36 patients by copy number qPCR (Figure 1B). In selected
cases, MLPA analysis confirmed the presence of two RAI1 alleles
(Figure 1C).
RAI1 Molecular Analysis
The RAI1 coding exons 3, 4, 5 and 6, including their intron-
exon boundaries, were sequenced for all 36 undeleted patients and
available parents and/or siblings. The identified coding variants
(excluding known SNPs) are listed in Table 1. In 4 patients, a
severe RAI1 mutation was identified; we classified these as ‘de novo’
variants. Patient M2377 was heterozygous for c.1449delC
[p.E484KfsX35], a frameshift mutation leading to a premature
stop codon (Figure 2A). This case was previously reported as
SMS159 [14]; this variation was absent from parental DNA.
Patient M2719 was heterozygous for a novel nonsense mutation,
c.1973G.A [p.W658X] (Figure 2B); parental DNA was not
Figure 1. RAI1 copy number analysis. (A) Representative images of two-color FISH analysis on metaphase chromosomes of lymphoblastoid cells
of an SMS patient without (M2717) and with (M2606) the 17p11.2 deletion. The probes were specific for the RAI1 locus (RP1–253P7; red) and for the
chromosome 17 centromere (green). The chromosomes were counterstained with DAPI (blue). (B) Copy number analysis by qPCR using TaqMan
primer-probe assays targeting exon 6 of RAI1 (Hs025670777_s1) and the endogenous control gene RNaseP. The comparative Ct method (RQ, relative
quantification) was used to determine the RAI1 gene copy number as shown for a non-deleted patient (M2485), a 17p11.2 deleted patient (M2173)
and a non-deleted patient with a familial RAI1 variant (M2900). (C) Results of MLPA copy number analysis, shown for 6 genes including RAI1 from the
P245-A2 kit. Results are shown for an SMS patient without the 17p11.2 deletion (M2543) and a patient with 17p11.2 deletion (M0119).
doi:10.1371/journal.pone.0022861.g001
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frameshift mutation, c.3103insC [p.Q1034PfsX31], leading to a
premature stop codon (Figure 2C). This case was recently reported
as SMS335 [22], and the C-nucleotide at position 3103 was
recognized as a frameshift mutation hotspot due to the presence of
a heptameric C-tract [22]. This variant was not present in parental
DNA. Patient M2911 had an unreported heterozygous frameshift
mutation c.548delT [p.L183RfsX69] (Figure 2D). Parental DNA
did not contain this variant.
Patient M2543 had a novel heterozygous missense variant,
c.725C.T [p.P242L], as well as a novel heterozygous silent
variant c.2907C.T [p.D969D] (Figure 2E) and 13 polyQ residues
on each allele. The missense variant c.725C.T was not present in
his mother (13 and 14 allelic polyQ residues) or brother (13 and 14
allelic polyQ residues). The silent variant c.2907C.T was present
in his mother, but not in his brother, indicating that these variants
occurred on separate alleles and that the c.2907C.T variant
occurred on an allele with 13 polyQ residues that was inherited
from his mother. The allele carrying the missense variant
c.725C.T was inherited from his father and carried 13 polyQ
residues (see pedigree Figure 2E). Since father’s DNA was not
available, we could not determine whether this variant was de novo
or paternally inherited, and therefore subgrouped this patient as
unclassified (Table 1).
In the previously reported patient SMS175 [13], with RAI1
p.Q1562R, we confirmed absence of the 17p11.2 deletion (M2390,
Table S1). However, we did not identify p.Q1562R in whole blood
or fibroblast DNA, raising the possibility of mosaicism.
Furthermore, we identified 3 novel heterozygous nonsynon-
ymous (missense) variants, one 3bp deletion and one synonymous
(silent) variant (Table 1), all of which were also found in one of the
parents. None of these ‘familial’ variants were reported SNPs, nor
were any identified in our other screened patients or reported in
previous RAI1 sequencing studies [9,10,11,12,13,14]. Patient
M2365 carried the missense variant c.5653G.A [p.D1885N] as
well as the silent variant c.3183G.A [p.T1061T], both of which
were identified in his unaffected father but absent from his
mother’s DNA; they are, therefore, expected to exist on the same
allele/in the same haplotype (see also Table S1). Of interest is that
p.D1885N is located in RAI1 exon 4, which is the first reported
RAI1 variant located in this exon.
Patient M2732 and her unaffected mother were heterozygous for
the unreported variant c.707A.T [p.Y236F]. Patient M2826 was
heterozygous for the novel missense variant c.3208G.A
[p.G1070R] as well as a novel silent variant c.4512G.T
[p.L1504L], which were both also identified in her mother
indicating that they may exist on the same allele/in the same
haplotype (see also Table S1). Her mother has a history of learning
problems (see Clinical Information S1). Patient M2867 had a novel
heterozygous in-frame deletion of 3 bp, c.3781_3783delGAG
[p.del1262E] that was also present in her unaffected father and
absent in maternal DNA. Patient M2900 carried a heterozygous
unreportedsilent variant c.1500G.A [p.P500P],which waspresent
in the homozygous state in his mildly dysmorphic mother (M2903)
and heterozygous in his brother with developmental delay (M2901)
and unaffected sister (M2902) (Figure 2F and Clinic Information
S1). The paternal DNA was not available for analysis. Further
familial molecular studies, including SNP analysis, identified a rare
reported SNP, c.3791A.G [p.E1264G] (rs61746214), heterozy-
gous in the proband (M2900), his mother, and his siblings.
The more common synonymous SNP c.837G.A [p.Q279Q]
(rs11078398) occurred homozygous in the proband and his siblings,
Table 1. RAI1 variants in SMS patients without 17p11.2 deletion identified in the current study.
Patient Nucleotide change Protein change ProbandpolyQ Father polyQ variants Mother polyQ variants Comments
de novo
M2377 c.1449delC p.E484KfsX35 14/14 NA no carrier NA no carrier Fig. 2A; SMS159 in [14]
M2719 c.1973G.A p.W658X 13/13 NA
a NA
a Fig. 2B
M2754 c.3103insC p.Q1034PfsX31 13/14 13/14 no carrier 13/13 no carrier Fig. 2C; SMS335 in [22]
M2911 c.548delT p.L183RfsX69 14/14 14/14 no carrier 14/14 no carrier Fig. 2D
unclassified








Fig. 2E for pedigree
familial




13/13 13/13 carrier of c.3183G.A
carrier of c.5653G.A
13/14 no carrier of
c.3183G.A no carrier
of c.5653G.A
p.D1885N is the first
reported variant in exon
4
M2732 c.707A.T p.Y236F 14/14 NA NA
b carrier of c.707A.T




14/14 NA 13/14 carrier of c.3208G.A
carrier of c.4512G.T
Mother is mildly affected
M2867 c.3781_3783delGAG p.del1261E 14/14 14/14 carrier of
c.3781_3783delGAG
14/14 no carrier of
c.3781_3783delGAG









see Fig. 2F for pedigree
NA: DNA was not available.
aThis case was classified as ‘de novo’ due to pathogenicity of the nonsense mutation, note that parental DNA could not be analyzed.
bOnly sequence around c.707A.T available, polyQ was not sequenced.
cReported rare SNP (rs61746214).
doi:10.1371/journal.pone.0022861.t001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22861Figure 2. SMS patients and their identified RAI1 variants. (A) Patient M2377 (pictured at age 20 years) carried the de novo frameshift variant
c.1449delC. (B) Patient M2719 (pictured at age 17 years) carried the de novo nonsense variant c.1973G.A. (C) Patient M2754 (pictured at age 18 years)
carried the de novo frameshift variant c.3103insC. (D) Patient M2911 (pictured at age 5 years) carried the de novo frameshift variant c.548delT. (E)
Patient M2543 (pictured at age 14 years) was heterozygous for the c.725C.T and c.2907C.T variants. The pedigree of his family contains the
genotypes of his mother (M2812) and his unaffected brother (M2811) for the identified variants as well as the informative SNP rs11078398 and the
polyQ repeat sequence. His father’s genotype could be partially reconstructed; no paternal DNA was available for sequencing. (F) Patient M2900
(pictured at age 6 years) was heterozygous for the c.1500G.A and c.3791A.G (rs61746214) variants, which were also present in his brother with
developmental delay (M2901) and in his unaffected sister (M2902). His family pedigree shows these variants as well as the informative SNP
rs11078398 and the polyQ repeat sequence. His father’s genotype could be partially reconstructed (no DNA was available).
doi:10.1371/journal.pone.0022861.g002
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indicate that neither the novel silent variant c.1500G.A, nor the
identified SNPs are likely to be related to the SMS phenotype in
proband M2900.
For the other 26 undeleted SMS patients, no novel RAI1
variants were detected in the coding region or intron/exon
boundaries, other than a variety of reported SNPs (Table S1A).
Missense Variant Analysis
Table 2 lists all RAI1 missense variants (detected in this study
and those previously reported), as well as nonsynonymous SNPs
(indicated with their rs identification numbers from dbSNP http://
www.ncbi.nlm.nih.gov/snp). Since the pathogenicity of missense
mutations is difficult to predict, we analyzed the potential
pathogenicity of each variant using different prediction software
programs (Polyphen, Panther and PMut). Please note that these
are predicted values only, not based on cellular data.
The identified p.P242L missense variant (patient M2543) has a
high probability to be deleterious predicted by at least 2 programs.
The previously published RAI1 missense mutations p.Q1562R
(SMS175) [13] and p.S1808N (SMS195) [13] were predicted to be
benign or ambiguous deleterious by all 3 prediction programs.
Interestingly, a recent report demonstrated that neither of these
two variants impair RAI1 nuclear localization or transcription
factor activity [19], suggesting that these variants may not cause
the SMS phenotype, or that other factors (post-translational
modifications, interactions) related to these mutations may induce
their SMS phenotype.
The familial missense variants p.Y236F, p.S1212G, p.D1885N,
and p.del1261E were predicted to be benign overall, based on at
least 2 prediction programs (except for p.del1261E, which could
only be analyzed by the Polyphen program, Table 2).
Of the 3 nonsynonymous SNPs, p.G90A (rs3803763) was
predicted to be benign, p.P165T (rs11649804) has variable
predictions, but p.E1264G (rs61746214) was predicted by Pmut
and Polyphen to be deleterious and warrants further research.
RAI1 is highly polymorphic; more than 30 SNPs are reported in
the coding region in dbSNP. All identified variants of our molecular
analyses are listed in Table 3. For each variant, the minor allele
frequency (MAF; the frequency of the SNP’s less frequent allele in a
given population) reported in dbSNP, as well as the MAF calculated
from our study are indicated in Table 3 (see also Table S1 for allele
distributions). Our SMS patient contingent was of Caucasian origin
(except patient M2900 who was Hispanic, and M2543 who had a
mother of Indian descent). For most variants, the MAF identified in
our study is similar to that reported in dbSNP, except for three
variants, rs8067439 and rs3803763, which occurred more fre-
quently in our SMS cohort and rs35686634, which occurred less
frequently in our SMS cohort (gray highlighted in Table 3).
SNP Haplotype Analysis
We attempted to reconstruct the haplotype for each patient by
assigning the variant nucleotides to each allele, using all
sequencing data including sequences from available family
members. For most patients, the listed haplotypes are the only
possible combination of variants; for other patients the haplotype
is the most likely prediction (Table S1). We prioritized the
presence of a ‘common haplotype’ allele (Haplotype H1 in Table
S1), and then assigned the nucleotides of the second allele. These
analyses revealed various allelic haplotypes among 72 studied
alleles, with one predominant haplotype existing on 44% of the
alleles (H1: 32 of 72 alleles, yellow highlighted in Table S1), one
moderately common haplotype existing on 15% of alleles (H2,
green highlighted) and several rare haplotypes, with existence
Table 2. Severity predictions of missense variants.










c.4685A.G p.Q1562R 1.639 21.77225 0.6285 (2) SMS175 in [13]
unclassified
c
c.725C.T p.P242L 2.724 22.22009 0.8389 (6) M2543 our study
c.5423G.A p.S1808N 1.19 22.7097 0.1546 (6) SMS195 in [13]
familial
c.707A.T p.Y236F 0.389 22.55309 0.0825 (8) M2732 our study
c.3634A.G p.S1212G 0.297 21.98231 0.5919 (1) Reported in [11]
c.5653G.A p.D1885N 1.436 23.01134 0.3235 (3) M2365 our study
c.3208G.A p.G1070R 1.769 23.57048 0.7923 (5) M2826 our study
c.3781_3783delGAG p.del1261E 1.92 - - (-) M2867 our study
SNP
rs3803763 c.269C.G p.G90A 0.124 21.00625 0.2039 (5)
rs11649804 c.494C.A p.P165T 2.274 22.6508 0.407 (1)
rs61746214 c.3791A.G p.E1264G 2.145 22.8526 0.7363 (4) M2900 our study
aEffect on the protein: Benign, italic print; Ambiguous, underlined; Deleterious, bold print.
bReliability score: Poor, italic print; Medium, underlined; Good, bold print.
cParental DNA was not available for testing.
doi:10.1371/journal.pone.0022861.t002
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white background, 17%) (Table S1).
RAI1 mRNA Expression
RAI1 mRNA expression levels were determined by qPCR on
RNA isolated from lymphoblastoid cells (Figure 3). SMS patients
with the common 17p11.2 deletion (M2370, M0119, M2844;
haploinsufficient for RAI1) had significantly (p,0.05) lower
expression of RAI1 mRNA, with an average of ,30% of control.
In addition, all patients with de novo RAI1 variants displayed
significantly decreased RAI1 expression (p,0.05 by at least one
statistical test) to about 52% of normal; cells from patient M2911
were not available. Decreased RAI1 expression was not only
determined in cells with RAI1 frame-shift and nonsense mutations
(36% in M2377, 59% in M2719, and 55% in M2754), but also in
the patient with a missense mutation (60% in M2543).
Expression levels varied among the familial RAI1 variants
(M2365, M2732, M2826, M2867, M2900) and three selected
non-deleted cases without novel RAI1 variants (M2390, M2647,
M2712). In this group, RAI1 expression varied from normal and
non-significant (98% in M2365, 104% in M2732, 80% M2647,
76% in M2712), to moderately but significantly (p,0.05)
decreased (61% in M2900 and 59% in M2390), to significantly
severely decreased (47% in M2826 and 21% in M2867). An
alternative normalizing gene (instead of b-actin), G6PC3 was used
for qPCR on selected mRNA samples from each group,
demonstrating that normalizing to a control assay with a similar
threshold cycle (Ct) as the RAI1 assays provided comparable
results to using b-actin as normalizing gene (Figure S1).
Since genomic copy number variations are a concern when
using EBV transformed cells [23,24], we also performed MLPA
analysis on genomic DNA from all lymphoblastoid cell lines
(Figure S2). We verified that all cell lines had two alleles for RAI1,
except for the 17p11.2 deleted cases (M2370, M0119, M2844),
who were confirmed to have one copy of the 17p11.2 genes RAI1,
LRRC48, and LLGL1. Cell lines M2365, M2370 and M2867
showed a variety of abnormal copy number variations outside the
17p11.2 region (Figure S2).
We were unable to analyze the translated amounts of RAI1
protein, since the commercially available RAI1 antibodies that we
tested (RAI-1 C-14 from Santa Cruz Biotechnology and LS-
C46854 from LifeSpan) did not yield a RAI1 signal by western
blotting of lymphoblastoid cell extracts.
Clinical Analysis
Detailed clinical descriptions of the cases with de novo and familial
RAI1 variants are provided in the Clinical Information S1.
Comparison of clinical features of our de novo subgroup with
previously reported RAI1 mutation and 17p11.2 deletion cases is
summarized in Table S2, and evaluated below. We provide
clinical comparison data with and without the ‘unclassified’ variant
M2543 included in the ‘de novo’ cohort, and mention where he is
an outlier. We did not analyze the RAI1 familial variants as a
discrete phenotypic group, partly due to the heterogeneity of their
RAI1 levels (Figure 3).
Growth parameters. Birth parameters for de novo RAI1
variant cases included term (mean 39.662.2 weeks) delivery and
appropriate-for-gestational age (AGA) birth weights and lengths,




c Protein change MAF dbSNP MAF Current study
d
rs3803763 c.269 C.G p.G90A 0.357
e 0.71
rs11649804 c.493 C.A p.P165T 0.242
f 0.29
rs11078398 c.837 A.G p.Q279Q 0.417
e 0.64
polyQ c.832–873 9–15 Q
rs8067439 c.1992 G.A p.P664P 0.017
f 0.79
rs61746214 c.3791 A.G p.E1264G NR
g 0.01
rs4925112 c.4311 T.C p.P1437P 0.034
f 0.03
rs35686634 c.4530 C.T p.P1510P 0.103
e 0.03
rs3818717 c.5601 C.T p.I1867I 0.298
f 0.36
- c.707 A.T p.Y236F - 0.01
- c.725 C.T p.P242L - 0.01
- c.1500 G.A p.P500P - 0.01
- c.2907 C.T p.D969D - 0.01
- c.3183 G.A p.T1061T - 0.01
- c.3208 G.A p.G1070R - 0.01
- c.3815 GGA._ p.del1261E - 0.01
- c.4512 G.T p.L1504L - 0.01
- c.5653 G.A p.D1885N - 0.01
adbSNP: http://www.ncbi.nlm.nih.gov/snp.
bNumbering is based on cDNA (NM_030665), with +1 corresponding to the A of the ATG initiation codon.
cMajor allele.Minor allele.
dBold print: significant differences from dbSNP.
eDetermined on AGI_ASP normal panel (Coriell Repositories, Camden, NJ).
fDetermined on HAPMAP CEU population.
gNR, not reported.
doi:10.1371/journal.pone.0022861.t003
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term) [25] and RAI1 mutation cases [11,12,13,14]. Among the de
novo RAI1 subgroup, four patients had current weights .98
th
centile (obese) and lacked short stature (,5
th centile), including the
youngest (M2911, 5y). Only M2543 appeared to be an outlier in
this group with weight in the normal range and short stature
(height ,2
nd centile). Head circumferences were normal for three
(M2719, M2754, M2911) and .95
th centile for one (M2377);
microcephaly (OFC,2
nd centile) was observed only in M2543, the
potential outlier.
The mean BMI for the de novo group (n=5; 31.3610.1 kg/m2)
was significantly higher than for the SMS 17p11.2 common
deletion group (n=49; 20.365.8 kg/m2) by the two-tailed
unpaired t-test (t=3.7, df=51; p,0.0005 (Figure 4A and 4B).
BMI values above 25.0–29.9 kg/m2 are considered overweight
and $30 kg/m2 are consistent with obesity as defined by the
Centers for Disease Control and Prevention (http://www.cdc.
gov/growthcharts/). Based on this classification, except for patient
M2543 (the missense variant outlier), all de novo RAI1 cases are
obese, including the youngest (M2911, 5y) in contrast to 57% (28
out of 49) of common 17p11.2 deletion cases (Figure 4B and 4C).
The observed frequency distribution of body types (Figure 4B) by
subgroup was not statistically significant (Chi square 6.0; p=0.42).
Age was significantly correlated to BMI for the entire study group
(Spearman’s rho 0.60; p,0.0001) (Figure 4C). However, analysis
by subgroup showed a significant correlation between BMI and
age for only the two largest subgroups: the common deletion cases
(n=49; Spearman’s rho 0.576; p,0.0001) and the non 17p11.2
deletion cases without RAI1 variants (n=24; Spearman’s rho
0.585; p=0.005). Both the de novo (n=5) and familial (n=5) RAI1
variant subgroups were non-significant (Figure 4C).
Neurobehavioral features. cases included: problems with
food intake and/or food foraging (5/5 de novo cases); nail yanking
(4/5 de novo; not M2543 outlier); and to a lesser extent anxiety/
mood shifts (5/5 de novo; including M2543 outlier). Speech delay
was seen less frequently in the de novo group (3/5) compared to
published deletion cases (.90%) and remains close to prior studies
(70%) [9,10]. All subjects without the 17p11.2 deletion and SMS
diagnosis in our study cohort had neurobehavioral features that
overlap with deletion cases (Table S2), likely reflective of referrals
for study by experienced clinicians. Behavioral features that might
distinguish the de novo subgroup from common deletion.
Figure 3. RAI1 mRNA expression in lymphoblastoid cells. RNA extracted from lymphoblastoid cells from SMS patients in 4 subgroups: cases
with common 17p11.2 deletion, de novo RAI1 variants (including the ‘unclassified’ variant M2543), familial RAI1 variants, and non-17p11.2 deleted
without identified RAI1 variants, as well as from 3 control cell lines were used for RAI1 mRNA expression analysis by qPCR. Two Taqman primer-probe
assays were used per sample (assay 1 and assay 2). Displayed values represent the relative quantification (RQ) compared to the average of all control
assays (set to 1). *: Average RQ of the sample is statistically different (p,0.05) from the average of all control cases (t: using the ANOVA post hoc
Tukey-Kramer test; g: using the ANOVA post hoc Games-Howell test).
doi:10.1371/journal.pone.0022861.g003
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22861Figure 4. Body mass index (BMI) analysis of SMS patients. Comparison of BMI (kg/m2) for common 17p11.2 deletion cases (n=49), and cases
with de novo (n=5, including unclassified variant M2543) or familial (n=5) RAI1 variants. (A) The mean BMI for each subgroup. The value for the de
novo RAI1 group was calculated with and without the outlier unclassified case (M2543) who carried an RAI1 missense variant. (B) Frequency of body
description type (normal, overweight,o robese) based on BMI values considering age (as plotted in (C)) and gender. Interpretation of BMI levels for age
2–20 years: underweight, ,5
th percentile; normal range, 5
th–85
th percentile; overweight, 85
th–95
th percentile; and obese, .95
th percentile. For adults:
underweight, BMI below 18.5; normal range, BMI 18.5–24.9; overweight, BMI 25–29.9; and obese, BMI 30 and over. (C) Comparison of BMI by age for
subjects 2–20 years of age. BMI percentile curves (5
th,8 5
th and 95
th) for ages 2–20 years were extracted from growth data from the Centers for
Disease Control and Prevention. BMI values are not plotted for 6 subjects over age 20 years; 3 with common deletions and 3 without deletions or RAI1
mutations (their values are displayed in upper left of the figure).
doi:10.1371/journal.pone.0022861.g004
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Hypotonia, frequent otitis media, ocular anomalies, dental
anomalies, hoarse voice, and brachydactyly occurred in our de
novo RAI1 cases with frequencies consistent with published 17p11.2
deletion cases (Table S2). Scoliosis was seen in 3/5 de novo (M2377,
M2719, M2754) cases, consistent with published frequencies for
common deletion (40–70%) and RAI1 mutation (36%) cases
[9,10]. Psychomotor delay, sleep disturbance and typical
behavioral features occurred in over 80% of the RAI1 cases
(Table S2). Hearing loss occurred in 4/4 de novo cases tested
compared with 60–79% for 17p11.2 deletions and 10–25% for
published RAI1 mutation cases [3,9,10]. Our two oldest cases
(M2377 and M2754) had sensorineural hearing loss (SNHL).
Discordant features with 17p11.2 deletion cases. Seizures
occurred in all but one of the de novo cases, compared with only
11–30% for deletion cases and 17% for published RAI1 mutation
cases [4,9,10]. Obstructive sleep apnea (OSA)/tonsillectomy/
adenoidectomy were more prevalent in the de novo cases (5/5)
compared to our deletion cases (50%). Cardiovascular and renal
abnormalities were not documented in any de novo cases, consistent
with prior reports [3,9,10]. While structural genitourinary
anomalies were absent, issues of incontinence and/or nighttime
enuresis were common, and frequent urinary tract infections
occurred in all three females in the de novo subgroup. Other
genital findings included hypogonadism (M2377) and labial
adhesions (M2911). With the exception of a bifid uvula
documented in M2719, facial clefts were absent. Immunological
abnormalities were not identified. In addition, failure to thrive
(FTT)/feeding issues were less frequent (3/5) in de novo RAI1
mutation cases compared to deletion cases (19/19) [26]. Both
gastroesophageal reflux disease (GERD) and constipation issues
occurred in de novo cases (2/5), but less frequently than reported for
deletion cases [27].
Discussion
In most microdeletion syndromes, haploinsufficiency of more
than one gene underlies the phenotype [28,29]. In others, such as
Alagille syndrome (deletion of 20p12; OMIM 118450) or
Rubinstein-Taybi syndrome (deletion of 16p13.3; OMIM
180849), haploinsufficiencies of a single gene (Jagged1 (JAG1)o r
CREBBP, respectively) accounts for all the characteristic features
[30,31,32]. In still other syndromes, haploinsufficiency of one gene
in the deleted region explains only some specific feature(s);
haploinsufficiency of the elastin gene accounts for the cardiac
defects in Williams-Beuren syndrome (deletion of 7q11.23; OMIM
194050) [33] and haploinsufficiency of the LIS1 gene explains the
lissencephaly of Miller-Dieker syndrome (deletion of 17p13.3;
OMIM 247200) [34,35].
SMS is considered a microdeletion syndrome in which
haploinsufficiency of multiple genes underlies the phenotypic
features [3,5,9]. However, heterozygous mutations in RAI1 have
been identified in clinically typical SMS patients without
detectable 17p11.2 deletions. This raises the issue of how RAI1
haploinsufficiency influences RAI1 RNA transcription, and which
clinical features of SMS result from RAI1 haploinsufficiency.
According to BioGPS (Human Gene Atlas U133A; http://
biogps.gnf.org) [36,37], RAI1 is expressed in 84 different human
tissues, including B-lymphoblasts. We employed lymphoblastoid
lines to assess RAI1 expression in our patients, after ruling out copy
number variations due to the immortalization process by MLPA
(Figure S2).
Our results indicated that haploinsufficiency of RAI1 (through
deletion of 17p11.2) results in a greater than 50% decrease in RAI1
expression (Figure 3). Other factors, likely deleted ancillary genes
in 17p11.2, may influence RAI1 expression to decrease below the
expected 50% level. For example, it was recently demonstrated
that HDAC4 haploinsufficiency (on chromosome 2q37) decreased
RAI1 mRNA expression to lower than 50% levels [38]. All our 4
patients with de novo RAI1 variants had approximately 50%
decreased RAI1 levels (Figure 3), likely due to RNA decay of the
nonsense (M2719) and frame-shift mutated (M2377, M2754,
M2911) alleles. These findings are consistent with RAI1 expression
levels reported for a haploinsufficient RAI1 mouse model [39].
Our ‘unclassified’ patient M2543 carried a missense (and a silent)
RAI1 variant and displayed decreased RAI1 expression; whether
his RNA expression level is directly related to these variants is
unknown. We found no obvious correlation between RAI1
haplotype (Table S1) and RNA expression (Figure 3).
Surprisingly, selected SMS patients without truncating RAI1
mutations displayed significantly decreased RAI1 expression in
both the familial variant group (47% in M2826; 21% in M2867,
and 61% in M2900) and in a non-deleted case (59% in M2390;
SMS175 in ref. [13]) (Figure 3). These reduced levels may help
explain their clinical SMS-like phenotype, supported by recent
data of patients mutated in HDAC4, showing impaired RAI1
mRNA expression (without RAI1 mutations) and exhibiting a
SMS-like phenotype [38]. In addition, sequence variations in non-
coding RAI1 exons 1 and 2, the 39untranslated region (UTR), or in
(conserved) intronic regions may underlie the decreased RAI1
levels. In addition, RAI1 expression may be affected by (epigenetic)
modifiers within or outside the common 17p11.2 deletion region;
environmental or physiological factors may also play a role [40].
These findings emphasize that RAI1 expression is a promising
genetic target for development of therapeutic interventions for
SMS.
In evaluating the clinical features of SMS in relation to
molecular results, we found that a high BMI and obesity are
characteristic of the de novo RAI1 variant cases (4/5), as previously
reported (6/9 or 67%) [3]. In our common deletion cases, the
frequency of obesity (28/49 or 57%; Figure 4B) was higher than
previously reported (4/31 or 13%) [3], perhaps reflecting age at
assessment and pubertal status. In the study by Edelman et al. [3],
median assessment ages were 15 years (de novo RAI1 mutation
cases) and 8 years (17p11.2 deletion cases), compared to 15 years
(de novo RAI1 cases) and 14 years (17p11.2 deletion cases) in our
analysis. A trend toward obesity in common deletion cases was
reported [25], beginning around age 9 years, coinciding with
pubertal onset, and reaching .95
th centile for weight in teenage
years to adulthood.
Past reports suggest that several features occur less often or are
less severe among RAI1 mutation cases compared to common
17p11.2 deletion cases. These include infantile hypotonia, short
stature, speech and motor delay, hearing loss, frequent otitis
media, and structural cardiac and renal defects [3,9,10].
Consistent with previously published reports, our de novo RAI1
variant cases (Table S2) were less cognitively impaired (mild
intellectual disability), lacked short stature (except for outlier
M2543), and had normal cardiac and renal structure. While delays
in growth (height/weight) in early childhood were previously
recognized for de novo RAI1 mutation cases [13], the frequency of
failure to thrive (FTT) and feeding issues in infancy has not been
documented. In our study group, FTT and early feeding issues
occurred less frequently among de novo RAI1 variant cases (3/5)
compared to reported for SMS deletion cases (19/19; 100%) [26].
We identified several features that occurred more frequently in
our de novo RAI1 variant cases than in previously reported cases.
Infantile hypotonia was documented more often in our de novo
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Seizures (with/without EEG abnormalities) also occurred more
frequently in our de novo (4/5) group than previously reported
(17%) [9,10]. As expected, behavioral features occurred across all
subgroups, reflecting syndrome-specific features that include sleep
disturbance and various maladaptive and self-injurious behaviors.
Interestingly, only 3/5 of our de novo RAI1 variant cases
demonstrated the characteristic ‘‘self-hug’’, which is more
consistent with the reported rate for deletion cases (50–80%)
compared to the 100% (9/9) previously reported for RAI1
mutation cases [3,9,10]. As expected, sleep disturbance was
universal, but we also documented increased symptoms of OSA
and/or T&A for our de novo (5/5) group. In addition, anxiety
issues, rapid mood shifts and emotional lability were present in 5/5
of our de novo RAI1 variant group, raising future research questions
concerning the role of RAI1 in neurodevelopment.
Only two clinical features (Table 4) demonstrated a significant
relationship to RAI1 mRNA levels, i.e., ocular abnormalities
(Mann-Whitney Z=22.35; p=0.0188) and object insertion
(Mann-Whitney Z=22.21; p=0.03). Some ocular abnormalities,
either strabismus (2/4), esotropia (3/4), or hyperopia (1/4), were
present in all our de novo RAI1 cases; this frequency is higher than
previously appreciated [9,10]; and more consistent with common
17p11.2 deletion cases (Table 4 and Table S2). Although object
insertion was significantly associated with lower RAI1 expression
levels (Table 4), this behavioral feature may reflect a bias of
ascertainment since it would lead to referral for RAI1 mutation
analysis of suspected SMS non-deleted cases.
While not significantly associated with RAI1 level, several
clinical features (Table 4) may differentiate cases with de novo RAI1
variants from the other sub-groups. All four de novo cases tested
demonstrated hearing loss in contrast to 25% (2/8) previously
reported, the role of RAI1 in hearing abnormalities is unknown
[3]. Since the Myosin 15A (MYO15A) gene, located in the 17p11.2
SMS critical region, was implicated as a candidate gene for the
hearing abnormalities of SMS [41], it is of interest to explore
MYO15A expression in SMS patients as well as the role of RAI1 in
MYO15A expression. The absence of immunologic abnormalities
(Table 4) in our de novo cases, versus the increased frequency
reported for deletion cases (23–50%) [42,43], suggests that a gene
other than RAI1 may regulate immune involvement in SMS. The
TNFRSF13B gene, located in 17p11.2, encoding the transmem-
brane activator and CAML interactor (TACI) protein, was
proposed as a candidate for the immune abnormalities, including
reduced IgA levels in SMS patients [43,44]. The presence of a
hoarse voice occurred in all our de novo cases, but was not
significantly related to RAI1 expression levels. Furthermore, no
apparent correlation between specific clinical features and RAI1
haplotype or polyQ repeat length (Table S1) could be identified. It
is of interest to note that a spina bifida occulta (SBO) variant
occurred in one de novo (M2377) and one familial (M2826) case,
both with RAI1 levels ,50%.
Failing to document a direct correlation between RAI1 level and
most features may reflect the small sample size and/or bias
introduced by features leading to referral for suspected SMS in
non 17p11.2 deletion cases. It is also possible that our group
categorization of subjects reflects an arbitrary designation. The
familial variants were not analyzed as a discrete clinical subgroup
due to the heterogeneity of their RAI1 levels. No feature(s)
emerged to distinguish the two females with low mRAI1 levels
(M2826, 47%; M2867, 20.7%) from others in the familial
subgroup. Familial cases may be similar to non-deletion cases
without RAI1 variants or, in cases where family members present
with subtle overlapping symptoms, further familial analysis of
RAI1 expression could shed more light on the role of the RAI1
variants. For example, our case M2900, the mother and
developmentally delayed brother both showed features not
observed in his cognitively normal sister (see Clinical Information
S1), yet all have the same familial RAI variant. Such cases reiterate
the importance of family studies to verify the inheritance of the
variant. We classified M2543, who has a severe missense RAI1
variant, as ‘unclassified’ since his father was unavailable for genetic
testing. Reasons to analyze the clinical and molecular findings of
M2543 with the ‘de novo’ subgroup were the severity of his missense
variant (Table 2) and his decreased RAI1 expression level of 60%
(Figure 3, Table 4), although this level was the highest in the de novo
group. On the other hand, M2543 appears to be an outlier from
the de novo group for several clinical features, including short
stature (,5
th centile), normal BMI (non-obese), less characteristic
facial appearance (See Figure 2E) with OFC at 2%, and increased
level of cognitive impairment with significant speech delay.
Our clinical analysis as well as our large group of undeleted
patients without detected RAI1 variants (26 patients, Table S1)
indicates that other genes may be involved in the complex SMS
phenotype. A future approach would be to determine RAI1
expression levels in this group of non-deleted cases as well as
expression levels for other genes in the 17p11.2 critical region that
have been implicated to play a role in some SMS features,
including MYO15A (hearing) [41], TNFRSF13B (immune) [43],
PEMT (fatty liver) [45], and ALDH3A2 (dry skin) [46]. We realize
that defects in other chromosomal regions could be present in
these patients, which will be pursued by whole genome array
studies, as recently described for other SMS patients [47].
An ancillary dividend of this study is our analysis of the
pathogenicity of RAI1 variants. It is reasonable to assume that the
nonsense and frame-shift RAI1 variants would lead to nonsense-
mediated decay [48]; the resulting haploinsufficiency of RAI1 could
lead to the SMS phenotype, as suggested for patients with the
common 17p11.2 deletion [7,49]. However, it remains unknown
how RAI1 missense mutations can underlie the SMS phenotype.
Our haplotype analysis showed that de novo and familial RAI1
variants did not appear to occur on a preferred haplotype (Table
S1). Our pathogenicity assessments of RAI1 missense variants
(Table 2) showed that p.P242L (M2543) was predicted to be
deleterious by at least 2 programs. However, before calling this
variant a mutation, paternal DNA (not available to us) should be
analyzed, and we therefore sub-grouped this patient as ‘unclassified’.
Two previously published missense variants, p.Q156R and
p.S1808N (SMS175 and SMS195 respectively [13]), were predicted
to be benign or ambiguously deleterious by all 3 prediction
programs (Table 2),and did not influenceRAI1 nuclear localization
or transcription activity [19]. This warrants further research
regarding the pathogenicity of these two variants.
Most familial missense variants were predicted to be benign by at
least 2 prediction programs. These predictions, in cases where the
carrier parents are apparently unaffected, render these variants
unlikely to be disease causing. The familial variant p.G1070R
(patient M2826) was predicted to be ambiguous and deleterious.
This variant was also present in the patient’s mother, who had
learning problems (see Clinical Information S1), and may play a
role in the severe clinical phenotype of the patient and mild
symptoms in her mother.
One of the three nonsynonymous RAI1 SNPs, p.E1264G
(rs61746214), was predicted to be deleterious, but familial analysis
showed that this variant may not be disease causing in patient
M2900 (Figure 2F). The allele frequency of rs61746214 is not
reported in dbSNP; we only identified this allele (of 72 analyzed) in
patient M2900. Since this individual was the only Hispanic in our
Molecular Aspects of RAI1 in SMS
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Hispanic population.
In sum, identification of additional de novo RAI1 cases is required
to further delineate phenotypic heterogeneity in this SMS
subgroup. Our study adds two newly ascertained de novo RAI1
mutation cases, one unclassified case, and provides further
assessment of two previously reported cases (M2377/SMS159
[14] and M2754/SMS335 [22]). As noted, early published RAI1
mutation cases may reflect a bias of ascertainment due to the
striking phenotypic similarity to deletion cases, especially with
respect to the physical and neurobehavioral features of the
syndrome that become more evident with age. Cases suspected to
have SMS, but without a 17p11.2 deletion, should prompt
consideration of RAI1 mutation analysis, if their features include
AGA term birth, childhood onset obesity (increased BMI for age),
ocular abnormalities, hoarse voice, middle ear dysfunction and
hearing loss, and behavioral aspects, especially self-injurious
behavior, nail damage, and problems regulating food intake (i.e.,
insatiable appetite), in the absence of immunological abnormalities
and cardiovascular or renal structural anomalies.
Materials and Methods
Ethics Statement
All patients were enrolled in NIH clinical protocol 01-HG-0109
approved by the National Human Genome Research Institute
(NHGRI) institutional review board to evaluate the clinical and
molecular manifestations of Smith-Magenis syndrome (www.
clinicaltrials.gov, NCT00013559). Written informed consent was
obtained from each patient or their parents. All clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki.
Study Group
Since universally agreed minimum diagnostic criteria for SMS
are lacking, patients were included based on the clinical
impression of experienced clinicians of clustering of features (i.e.,
facial appearance, unusual sleep pattern, behavioral and develop-
mental concerns) suggestive of SMS.
Clinical data for participating subjects were derived from chart
review of medical records and genetic evaluations at the NIH or
offsite. Descriptive statistics including weight and height percen-
tiles and body mass index (BMI) were calculated using an on-line
body surface area calculator for medication doses (http://www.
halls.md/body-surface-area/bsa.htm). For statistical analysis,
growth parameters of ‘de novo’ and ‘familial’ RAI1 variants were
compared to a common 17p11.2 SMS deletion group of 49
patients (30 female/19 male; mean age 9.668.4 years; range 1.4 to
49 years), also evaluated under our NIH clinical protocol.
Peripheral blood was collected from the patients and employed
for extraction of genomic DNA and for Epstein Barr Virus (EBV)
immortalization of B-lymphocytes, using standard protocols.
Primary cultures of epidermal fibroblasts were obtained from
selected patients from a forearm skin biopsy or from tissue
procured from a surgical sample and cultured as previously
described [50].
Cytogenetic Analysis
A subset of patients enrolled in our protocol had prior fluorescent
in situ hybridization (FISH) results from studies performed by outside
laboratories. For most patients without prior cytogenetic studies, we
performed FISHwithDNAprobesspecificforthe RAI1locus(RP1–
253P7), as well as a distal SMS-REP (RP11–416I2) and a proximal
SMS-REP (RP5–836L9) 17p11.2 probe, as described [51].
Copy Number Analysis
Genomic DNA (gDNA) of all enrolled patients was subjected to
RAI1 copy number analysis by quantitative PCR (qPCR). For
qPCR, TaqMan primer-probe assays targeting exon 6 of RAI1
(Hs025670777_s1) and the endogenous control gene RNaseP were
purchased from Applied Biosystems (Foster City, CA). gDNA
samples of SMS patients, along with control samples, were PCR-
amplified in triplicate as described [52] for both assays on an ABI
PRISM 7900 HT Sequence Detection System (Applied Biosystems).
The comparative Ct method was used to determine the RAI1 gene
copy number [52,53,54]. For copy number analysis by multiplex
ligation-dependent probe amplification (MLPA), the P245-A2
Microdeletion Syndromes-1 kit was employed, which includes a
probe for RAI1, following the manufacturer’s recommendations
(MLPAHMRC-Holland,Amsterdam,The Netherlands).Genescan-
ROX 500 (Applied Biosystems) was added to the reaction mixtures
to facilitate estimation of fragment sizes. MLPA fluorescent PCR
products were separated on an ABI 31306lg e n e t i ca n a l y z e r
(Applied Biosystems). Peak height values obtained in probands were
compared to those obtained in healthy controls, using GeneMarker
1.8 software (SoftGenetics, LLC, State College, PA).
RAI1 Sequence Analysis
Some patients were referred by their clinicians for commercial
RAI1 sequencing of exon 3 (GeneDx, Gaithersburg, MD) and
enrolled in the NIH protocol with a confirmed RAI1 mutation.
DNA samples of these referred RAI1 mutated patients, as well as
DNA of our NIH contingent of other enrolled non-17p11.2
deleted SMS-like patients, were subsequently analyzed for all 4
RAI1 coding exons, to accurately assess all gene variants (including
SNPs). Primers were designed to amplify the 4 coding exons of
RAI1, including their intronic boundaries in 22 amplicons (primer
sequences available on request). Standard PCR amplification
procedures were employed. All amplified products were directly
sequenced using the BigDye 3 Terminator chemistry (Applied
Biosystems) and separated on an ABI 31306l genetic analyzer
(Applied Biosystems). Data were evaluated using Sequencher 4.8
software (Gene Codes Corporation, Ann Arbor, MI).
Missense Variant Prediction Tools
The effect of missense variations on protein function was
evaluated using the mutation prediction programs POLYPHEN,
PANTHER and PMUT.
POLYPHEN. (http://genetics.bwh.harvard.edu/pph/; POLY-
morphism PHENotyping) predicts the effect of an amino acid
substitution on the structure and function of a protein.
POLYPHEN predictions are based on empirical rules that are
applied to the sequence, as well as phylogenetic and known
structural information that characterize the substitution. The
Position-Specific Independent Counts (PSIC) is calculated for the
two different alleles and the score for wild type and variant
mapping to the known 3D structure [55].
PANTHER. (http://www.pantherdb.org/; Protein ANalysis
THrough Evolutionary Relationships) estimates the likelihood
of a non-synonymous variant to cause loss of function of the
protein. The output, the subPSEC (substitution position-specific
evolutionary conservation), is the negative logarithm of the
probability ratio of the wild-type and mutant amino acids at a
particular position based on a library. This library contains over
5,000 protein families and 30,000 subfamilies, each represented by
a multiple sequence alignment and Hidden Markov Model.
PANTHER subPSEC scores are continuous from 0 to 210. A
value of 0 is interpreted as a functionally neutral variant; the more
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The cutoff value suggested is 23 [56,57,58].
PMUT. (http://mmb2.pcb.ub.es:8080/PMut/) uses neural
networks that have been trained with a large database of
disease-associated and neutral variants to predict the impact of a
given amino acid substitution. The output gives a neural network
(NN) value between 0 and 1 (the higher this value, the more
deleterious the variant) and a confidence value between 0 and 9
(the higher this value, the more reliable the NN) [59].
RAI1 mRNA Expression
Total RNA was isolated from patients’ or control lymphoblas-
toid cells using the RNeasy Mini-Kit (Qiagen, Valencia, CA).
RNA was subsequently treated with DNase (Applied Biosystems).
RNA concentration and purity were assessed on a NanoDrop ND-
1000 spectrophotometer (Thermo Fisher Scientific, Wilmington,
DE). First strand cDNA was synthesized using a high capacity
RNA-to-cDNA kit (Applied Biosystems). qPCR was performed
utilizing two RAI1 Assays-On-Demand Taqman primer-probe
assays (Applied Biosystems), Hs00430773_m1 (Assay 1; located at
the RAI1 exon 2–3 boundary) and Hs01554690_m1 (Assay 2;
located at the RAI1 exon 3–4 boundary), and a control assay for
the b-actin housekeeping gene (Hs99999903_m1). PCR amplifi-
cations were performed on 100 ng of cDNA using TaqMan Gene
Expression Master Mix reagent (Applied Biosystems) and were
carried out on an ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems). Results were analyzed with the
comparative Ct method as described [53,60]. All assays were
performed at least three times, and each sample was measured in
triplicate. Displayed values in Figure 3 represent the relative
quantification (RQ) normalized to the average of all control assays
in all three control cell lines (arbitrary set to 1). For verification of
results with an alternative control gene (to b-actin) with a similar
threshold cycle (Ct) as RAI1,aG6PC3 TaqMan assay
(Hs00292720_m1) was used on selected mRNA samples (Figure
S1). The average Ct for both RAI1 assay 1 and G6PC3 assays was
,34–35 cycles in lymphoblastoid mRNA.
Statistics
Data were compiled for statistical analysis using Statview.
Differences between data groups were evaluated for significance
using different standard statistical tests depending on the variables.
For RNA expression data (Figure 3), where the number of
patients/datapoints was not equal between the groups, the
ANOVA post hoc Tukey-Kramer as well as the ANOVA
Games-Howell tests were used. For phenotype-genotype correla-
tions, specific tests (indicated in the text where used) included two-
tailed unpaired t-test, non-parametric tests, Spearman’s rank
correlation coefficient (Spearman’s rho). Chi-Square tests of
independence were employed depending on whether the depen-
dent variable was continuous or categorical. Given the concern for
a potential outlier (M2543), the nonparametric Mann-Whitney
test was used for means analysis of phenotypic features (Table 4).
All data are presented as the mean 6 SD (standard deviation). A p-
value less than 0.05 was considered statistically significant.
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